Study explains why interferon defenses failed in some severe COVID-19 cases

Researchers say some severe COVID-19 patients carried pre-existing B cells and autoantibodies that neutralized type I interferons, blunting one of the body’s earliest antiviral defenses. The Cell study could help identify people at higher risk before infection and guide future therapies for COVID-19 and other viral threats.

Why it matters: - Type I interferons are one of the body’s first defenses against viral infection, so disabling them can give the coronavirus an early advantage. - The findings may help clinicians identify people at higher risk of severe COVID-19 before infection happens. - The research may also be relevant to seasonal influenza and future coronavirus outbreaks.

What happened: - Researchers studying severe COVID-19 found that some patients had autoantibodies that neutralized type I interferons. - The study was published in Cell and focused on how harmful autoantibodies develop in patients with severe disease. - The work involved scientists affiliated with institutions in France, Switzerland, Canada, Spain, Belgium, Saudi Arabia, Sweden, Denmark, Italy, the USA, Estonia, and the United Arab Emirates.

The details: - The researchers found a large and diverse population of B cells programmed to recognize interferons in affected patients. - The immune response showed extensive somatic hypermutation and prolonged affinity maturation. - Using patient-derived monoclonal antibodies, X-ray crystallography, and AlphaFold3-based structural analysis, the team examined hundreds of antibodies. - The antibodies targeted three major B-cell epitopes covering the principal regions of type I interferons. - The antibodies were capable of recognizing and neutralizing different type I interferons, including interferon-α and interferon-ω. - Prof. Rabih Halwani of the University of Sharjah said the abnormal immune response was detectable before life-threatening disease, pointing to a pre-existing defect rather than a consequence of infection. - Prof. Halwani said the immune system had refined a response against the body’s own interferons through affinity maturation.

Between the lines: - The study suggests the problem is not just that autoantibodies appear during severe illness; some may already exist in a mature, persistent autoimmune B-cell response. - That matters because pre-existing autoantibodies can disable the interferon alarm system right when early antiviral defense is most needed. - The findings offer a possible explanation for why some people progress to severe disease while others do not. - The research may also help explain risk in older adults and people with defects in immune tolerance.

What's next: - The findings could inform new therapeutic strategies aimed at protecting interferon signaling. - Clinicians may eventually use this type of immune profiling to flag patients at elevated risk before infection. - The authors say the work supports a model linking a germinal-center-derived memory B-cell response to severe viral disease.

The bottom line: - In some severe COVID-19 patients, the immune system appears to have built a durable response against its own antiviral alarm, leaving the body less able to fight the virus early.